Compare · MDLN vs PROF
MDLN vs PROF
Side-by-side comparison of Medline Inc. (MDLN) and Profound Medical Corp. (PROF): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MDLN and PROF operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $48.08B, about 208.6x PROF ($230.5M).
- Over the past year, MDLN is down 11.8% and PROF is up 4.5% - PROF leads by 16.3 points.
- MDLN has been more active in the news (7 items in the past 4 weeks vs 6 for PROF).
- MDLN has more recent analyst coverage (25 ratings vs 8 for PROF).
- Company
- Medline Inc.
- Profound Medical Corp.
- Price
- $35.95-1.74%
- $6.02-4.75%
- Market cap
- $48.08B
- $230.5M
- 1M return
- +11.97%
- +2.56%
- 1Y return
- -11.77%
- +4.51%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- News (4w)
- 7
- 6
- Recent ratings
- 25
- 8
Profound Medical Corp.
Profound Medical Corp., together with its subsidiaries, operates as a medical technology company that develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system used for magnetic resonance imaging scanner in hospitals and treatment facilities. The company also offers Sonalleve, a therapeutic platform for the treatment of uterine fibroids and palliative pain relief associated with metastases in bone, as well as non-invasive treatment of uterine fibroids. Profound Medical Corp. is headquartered in Mississauga, Canada.
Latest MDLN
- SEC Form 8-K filed by Medline Inc.
- Medline to build Midwestern network with new 800,000-square-foot facility in Van Buren Township, Mich.
- SEC Form 4 filed by Medline Inc.
- Medline launches enhanced TrackPoint™ to simplify inventory management for post-acute care
- SEC Form 4 filed by Medline Inc.
- MEDLINE INC. MDLN INVESTORS: Contact Kirby McInerney LLP About the Firm’s Securities Investigation Following 12.8% Share Drop
- Medline to report third quarter 2026 results on November 4, 2026
- INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Medline Inc. to Contact Law Firm
- Medline announces participation in the Morgan Stanley 24th Annual Global Healthcare Conference
- SEC Form 4 filed by Chief Executive Officer Boyle James M
Latest PROF
- SEC Form 8-K filed by Profound Medical Corp.
- TULSA Abstracts at the 15th Interventional MRI Symposium Strengthen Real-World Evidence, Clinical Differentiation, and Platform Expansion Opportunity
- SEC Form 8-K filed by Profound Medical Corp.
- Profound Medical and Telix Pharmaceuticals Enter Co-Education Agreement to Advance PSMA-Informed Prostate Care
- SEC Form 8-K filed by Profound Medical Corp.
- Profound Medical Reports Strong Preliminary Third Quarter 2026 Revenue
- Profound Medical Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Profound Medical to Participate in Lake Street’s 10th Annual Best Ideas Growth Conference
- Profound Medical Corp. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Profound Medical Further Strengthens Executive Leadership Team with Appointment of Richard Fabian as President